Waltz Health Launches New Direct-to-Employer Access Model for Obesity Management Medications
Waltz Health announced it’s introducing an innovative direct-to-employer model for FDA-approved obesity management medications, set to launch in January 2026. The approach provides fixed pricing, clinical review, fulfillment support, and digital engagement:
CHICAGO – November 21, 2025 — Waltz Health, an EVERSANA company developing smarter, technology-enabled ways to price, distribute and prescribe medications, today announced a direct-to-employer (DTE) access model for FDA-approved obesity management medicines. The first-of-its-kind program is designed to give self-insured employers a new pathway to deliver coverage for these medicines with clinical safeguards, transparent pricing and end-to-end employee support. The model will be available directly to employers and through the consulting channel as part of broader benefits strategies.
Launching January 1, 2026, the model integrates fixed pricing with a fulfillment and support ecosystem that aligns with each employer’s existing benefit structure. Waltz Health provides real-time eligibility screening, pharmacy routing, prescription adjudication and ongoing patient engagement to simplify the experience for employees while giving employers transparency and control.